Kathleen Marable-Burke
Primary Care · Grove City, OHNPI 1033873880
Payments from drug & device makers
Across 71 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$165
- AbbVie$157
- Novo Nordisk$121
- Exact Sciences$119
- Dexcom, Inc.$113
- Lilly USA, LLC$112
- plus $594 from 15 others
What the payments were for
- Food & beverage$1,381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $165 |
| AbbVie | 7 | $157 |
| Novo Nordisk | 7 | $121 |
| Exact Sciences | 5 | $119 |
| Dexcom, Inc. | 4 | $113 |
| Lilly USA, LLC | 6 | $112 |
| Pfizer | 5 | $101 |
| GSK | 5 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Bayer | 3 | $49 |
| Abbott | 2 | $33 |
| Merck | 2 | $32 |
| Boehringer Ingelheim | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Shield Therapeutics Inc | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
How this compares
$1,381 in reported general payments places this provider in the 75th percentile of 321 primary care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 37 | $56,198 |
| OzempicSemaglutide | 31 | $48,994 |
| EliquisApixaban | 27 | $28,156 |
| MounjaroTirzepatide | 11 | $21,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,909 |
| JardianceEmpagliflozin | 15 | $15,321 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,495 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,133 |
| Arnuity ElliptaFluticasone Furoate | 14 | $2,849 |
| Atorvastatin Calcium | 166 | $2,456 |
| Famotidine | 105 | $1,913 |
| Gabapentin | 88 | $1,634 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,604 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,544 |
| Azelastine Hcl | 33 | $1,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $165 | $56,19837 claims |
| Novo NordiskOzempic | $121 | $48,99431 claims |
| PfizerEliquis | $101 | $28,15627 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $90 | $23,75739 claims |
| Lilly USA, LLCMounjaro | $112 | $21,86311 claims |
| Boehringer IngelheimJardiance | $30 | $15,32115 claims |
| AbbVieSynthroid | $157 | $98614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 321 primary care providers in Ohio.
Other primary care in Grove City
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Regan HeagenFindlay$8K
- Zachary HaleBeavercreek$7K
- Katherine ElliotWesterville$7K
- Stephanie EmmettMayfield Heights$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.